Spyre TherapeuticsSYRE
Market Cap: $1.55B
About: Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. A range of pharmaceutical options to address IBD exists, including anti-inflammatory drugs, immunosuppressants, and biologics.
Employees: 30
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
176% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 17
74% more call options, than puts
Call options by funds: $61K | Put options by funds: $35K
16% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 25
10.64% more ownership
Funds ownership: 89.71% [Q1] → 100.36% (+10.64%) [Q2]
4% more funds holding
Funds holding: 103 [Q1] → 107 (+4) [Q2]
1% less capital invested
Capital invested by funds: $1.22B [Q1] → $1.2B (-$17.5M) [Q2]
40% less funds holding in top 10
Funds holding in top 10: 5 [Q1] → 3 (-2) [Q2]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Wedbush David Nierengarten 57% 1-year accuracy 35 / 61 met price target | 48%upside $45 | Outperform Initiated | 4 Sept 2024 |